Summary
This prediction ended on 24.08.10 with a price of €2.35. With a performance of -3.29%, the BUY prediction for Evotec SE by Riccardo closed slightly in the red. Riccardo has 50% into this predictionEvotec is a German-based biotech company that provides drug discovery and development solutions to pharmaceutical and biotechnology companies. The company operates in the fields of neuroscience, immunology, oncology, and infectious diseases, and its services include hit identification, target validation, and preclinical and clinical development. Evotec has partnerships with major pharmaceutical companies and has developed its own pipeline of drugs, with a focus on developing treatments for conditions such as Alzheimer's disease and diabetes. The company is listed on the Frankfurt and NASDAQ stock exchanges and has a market capitalization of approximately €5.5 billion.
Performance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Evotec SE | -7.014% | -7.014% | -70.892% | -85.241% |
iShares Core DAX® | -1.414% | 7.218% | 17.151% | 15.732% |
iShares Nasdaq 100 | -2.316% | 4.450% | 18.360% | 30.945% |
iShares Nikkei 225® | -2.756% | 10.071% | 10.704% | 2.733% |
iShares S&P 500 | -1.849% | 4.760% | 19.639% | 34.852% |
Comments by Riccardo for this prediction
In the thread Evotec AG diskutieren
Kaufenswert
Das Hamburger Biotechnologie-Unternehmen Evotec hat in den ersten sechs Monaten den Umsatz um ein Drittel gesteigert und operativ schwarze Zahlen geschrieben. Unternehmenschef Werner Lanthaler hob am Donnerstag die Prognose für den Umsatz an und rechnet nun mit einem Erlösanstieg auf 52 bis 54 Millionen Euro, nachdem die Gesellschaft bisher 48 bis 50 Millionen Euro in Aussicht gestellt hatte.